Seres Therapeutics has presented interim results from an ongoing Phase II trial which has sent company stock spiralling downward, as …
New CCO Ogburn joins Cori Clinical
Claris reports visual acuity gains with experimental LSCD treatment
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics

